Clinical trials: Atorvastatin
Hypertension, Hypercholesterolemia
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension…
- Conditions
- Hypertension, Hypercholesterolemia, Angina Pectoris
- Trial name
- NCT01190007
- Testing
- Caduet
- Where
- 20 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hyperlipidemia
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
- Trial name
- NCT00138762
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 154 sites in United States, Belgium and 6 more
- Volunteers
- 3,800 people
- Sponsor
- Pfizer
Coronary Arteriosclerosis, Hypercholesterolemia
Comparative Atorvastatin Pleiotropic Effects
The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented…
- Trial name
- CAP (NCT00163202)
- Testing
- Blood samples, Atorvastatin
- Where
- 74 sites in Canada, Czechia and 5 more
- Volunteers
- 330 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Hypercholesterinemia
A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers
To evaluate the influence of BR1017-1 and BR1017-2 on pharmacokinetics and safety when administered separately or co-administered to healthy volunteers.
- Trial name
- NCT05372380
- Testing
- BR1017-1, BR1017-2
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Dyslipidemias
A Study of LY2484595 in Japanese Subjects
The purpose of this study is to determine if 12 weeks of treatment with LY2484595 administered as a monotherapy will significantly increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein…
- Trial name
- NCT01375075
- Testing
- LY2484595, Atorvastatin
- Where
- 5 sites in Japan
- Volunteers
- 165 people
- Sponsor
- Eli Lilly and Company
Hypercholesterolemia
Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia
The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with additional statin therapy on cholesterol levels in treating patients with elevated cholesterol.
- Trial name
- NCT00249899
- Testing
- Lapaquistat acetate and stable statin therapy, Stable statin therapy
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 649 people
- Sponsor
- Takeda
Cardiovascular Diseases
Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease
The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and atorvastatin combination therapy compared to atorvastatin monotherapy in patients at risk for cardiovascular disease.
- Trial name
- NCT00770575
- Testing
- Pioglitazone and atorvastatin, Atorvastatin
- Volunteers
- 148 people
- Sponsor
- Takeda
Hypercholesterolemia, Dyslipidemia
Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin
The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin.
- Trial name
- NCT01163851
- Testing
- 4 mg/kg, 0.5 mg/kg
- Where
- 5 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Coronary Arteriosclerosis
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy.
- Trial name
- NCT00380939
- Testing
- Atorvastatin, Pravastatin
- Where
- 36 sites in United States
- Volunteers
- 600 people
- Sponsor
- Pfizer
Calcinosis, Arteriosclerosis
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients.
- Conditions
- Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary
- Trial name
- NCT00211939
- Testing
- calcium acetate, sevelamer, atorvastatin
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Nabi Biopharmaceuticals
Diabetes Mellitus, Type 2
A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
The aim of this 20 week study is to show that glimepiride/atorvastatin fixed dose combination tablet is safe and as effective as atorvastatin + glimepiride combination taken as separate tablets, in improving glycaemic control…
- Trial name
- NCT01495013
- Testing
- 1mg Glimepiride/10mg Atorvastatin FDC, 2mg Glimepiride/10mg Atorvastatin FDC, 3mg Glimepiride/10mg Atorvastatin FDC
- Where
- 33 sites in Malaysia, Mexico and 4 more
- Volunteers
- 427 people
- Sponsor
- GlaxoSmithKline
Plaque, Atherosclerotic
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
This study is to evaluate the effect of Inclisiran on coronary atherosclerosis using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in patients with acute myocardial infarction and elevated low-density…
- Trial name
- V-ACCELERATE (NCT06372925)
- Testing
- atorvastatin, IVUS/OCT, inclisiran
- Where
- 19 sites in China
- Volunteers
- 318 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Adult Subject, Overweight Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects.
- Trial name
- NCT06601517
- Testing
- Repaglinide, Atorvastatin, Digoxin
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Hypercholesterolaemia
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
The purpose of this study is to compare the effectiveness and safety of rosuvastatin 5mg in lowering blood cholesterol, compared to one other medicine, atorvastatin 10mg in Asian patients in the UK.
- Trial name
- NCT00427960
- Testing
- Dietary advice, rosuvastatin, atorvastatin
- Where
- 9 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
T2DM
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin，Atorvastatin and Valsartan in healthy subjects.
- Trial name
- NCT05681273
- Testing
- Chiglitazar, Empagliflozin, Atorvastatin
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Hypercholesterolemia
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab administration as add-on therapy to non-statin lipid modifying therapy (LMT) including diet therapy alone or the lowest…
- Trial name
- ODYSSEY-NIPPON (NCT02584504)
- Testing
- Alirocumab, Atorvastatin, Non-statin Lipid-Modifying Therapy
- Where
- 30 sites in Japan
- Volunteers
- 163 people
- Sponsor
- Sanofi
Hypercholesterolaemia
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Primary Objective: To collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings.
- Trial name
- NCT03415178
- Testing
- Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY)
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sanofi
Multiple Sclerosis
Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis
This research study is being done to evaluate the safety of BHT-3009 alone and when combined with atorvastatin (Lipitor) in patients with multiple sclerosis (MS).
- Trial name
- NCT00103974
- Testing
- BHT-3009-01
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Bayhill Therapeutics
Hyperlipidemias
A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
This study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending doses (MAD) of SGB-3403 when single administered subcutaneously to healthy volunteers and multiple administered…
- Trial name
- NCT06239714
- Testing
- SGB-3403, Atorvastatin
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.
Coronary Heart Disease
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
The purpose of this study is to compare the efficacy between two lipid lowering treatments, rosuvastatin (10-40 mg) and atorvastatin (20-80 mg) in reducing low-density lipoprotein cholesterol (LDL-C) levels after 16 weeks of…
- Trial name
- NCT00235950
- Testing
- Rosuvastatin or atorvastatin or simvastatin and clopidogrel
- Where
- 18 sites in Sweden
- Volunteers
- 255 people
- Sponsor
- AstraZeneca